Alpine is a development-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer, inflammatory disorders, and other diseases. Alpine’s proprietary Variant Immunoglobulin Domain™ (“vIgD™”) scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. Alpine’s vIgD platform creates molecules which can be formatted in many different ways, including standard Fc fusion proteins, localized Fc fusion proteins, and monoclonal antibody fusion proteins as well as formulated as a Transmembrane Immunomodulatory Protein (“TIP™”) or as a Secreted Immunomodulatory Protein (“SIP™”). Alpine expects to request regulatory approval to begin human clinical trials of ALPN-101, Alpine’s dual ICOS/CD28 antagonist program, in the second half of 2018. Alpine expects the target indication for the ALPN-101 program will be inflammatory disorders. Alpine currently does not have any drugs commercially available and none of its drug candidates have obtained approval of the FDA or any similar foreign regulatory authority.